By Colin Kellaher
Beam Therapeutics has hired Sravan Emany as the biotechnology company's next chief financial officer.
Beam on Friday said Emany, who joins the Cambridge, Mass., company on Dec. 19, was most recently served as chief financial and operating officer at Ironwood Pharmaceuticals, which announced his pending departure late Wednesday.
Beam said Emany, 47 years old, will receive an annual base salary of $575,000, a sign-on bonus of $325,000 and an annual incentive bonus with a target of 50% of his base pay.
Beam earlier this year said its previous chief financial officer, Terry-Ann Burrell, was leaving to join JPMorgan Chase.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 06, 2024 07:16 ET (12:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。